Scholarlink

<p>Regulatory T cells (Treg) play immunosuppressive roles in lung cancer and are key biomarkers in cancer immunology. Using scRNA-seq and stereo-seq, we aimed to identify a novel circulating Treg subtype in non-small cell lung cancer (NSCLC). We developed a regional overlap-expression rate (rOER) system with cell identity marker gene panels (ciMGPs) to quantify T cell subtype specificity across pre/post-operative blood, 31 diseases, and in 17 organs. A Treg subtype (Treg<sup><i>fci</i></sup>, FOXP3<sup>+</sup>CTLA4<sup>+</sup>IL2RA<sup>+</sup>) was identified and validated for disease-, organ-, and time-specific characteristics across spatializations, temporalizations, diseases, and prognoses. Treg<sup><i>fci</i></sup> was prominently enriched in pre-operative blood and NSCLC tissue but markedly decreased or was absent post-operatively. Spatial transcriptome and multiplex immunostaining revealed that Treg<sup><i>fci</i></sup> localized primarily to the interface between NSCLC and normal tissues, as well as in specific micro-niches. ETS Proto-Oncogene 1 (<i>ETS1</i>) was upregulated in Treg<sup><i>fci</i></sup>, confirmed by knockdown and knockout experiments. <i>ETS1</i> facilitated Treg<sup><i>fci</i></sup> migration from circulation into tumor tissues via cancer cell-derived chemoattraction. Interactions between <i>ETS1</i> and Treg<sup><i>fci</i></sup> ciMGPs, and between intracellular organelles, were found to modulate metabolism and mitochondrial function. These findings highlight the importance of Treg<sup><i>fci</i></sup> in understanding the molecular mechanism by which Tregs maintain the balance between systemic and local immune ecosystems. ETS1’s regulation of Treg<sup><i>fci</i></sup> transcriptomic and metabolic profiles were confirmed in human PBMCs treated with an <i>ETS1</i> inhibitor and in lung tissues from mice<sup><i>ETS1-cKO</i></sup> mice. Furthermore, Treg<sup><i>fci</i></sup> and <i>ETS1</i> represent a distinct molecular signature of T cells and potential therapeutic targets for clinical intervention in lung cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Single-cell identifies and validates human circulating Treg subtype/state Tregfci in non-small cell lung cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月3日

查看全文
  • Xuanqi Liu,
  • Yifei Liu,
  • Wanxin Duan,
  • Jianming Weng,
  • Hao Dai,
  • Fangming Liu,
  • Lingyan Wang,
  • Mengjia Qian,
  • Bijun Zhu,
  • Shuyao Wu,
  • Youqiong Ye,
  • Muhan Yuan,
  • Shaojun Hong,
  • Mingjie Wang,
  • Yunfeng Cheng,
  • Tianxiang Chen,
  • Duojiao Wu,
  • Yuanlin Song,
  • Xiangdong Wang

摘要

Regulatory T cells (Treg) play immunosuppressive roles in lung cancer and are key biomarkers in cancer immunology. Using scRNA-seq and stereo-seq, we aimed to identify a novel circulating Treg subtype in non-small cell lung cancer (NSCLC). We developed a regional overlap-expression rate (rOER) system with cell identity marker gene panels (ciMGPs) to quantify T cell subtype specificity across pre/post-operative blood, 31 diseases, and in 17 organs. A Treg subtype (Tregfci, FOXP3+CTLA4+IL2RA+) was identified and validated for disease-, organ-, and time-specific characteristics across spatializations, temporalizations, diseases, and prognoses. Tregfci was prominently enriched in pre-operative blood and NSCLC tissue but markedly decreased or was absent post-operatively. Spatial transcriptome and multiplex immunostaining revealed that Tregfci localized primarily to the interface between NSCLC and normal tissues, as well as in specific micro-niches. ETS Proto-Oncogene 1 (ETS1) was upregulated in Tregfci, confirmed by knockdown and knockout experiments. ETS1 facilitated Tregfci migration from circulation into tumor tissues via cancer cell-derived chemoattraction. Interactions between ETS1 and Tregfci ciMGPs, and between intracellular organelles, were found to modulate metabolism and mitochondrial function. These findings highlight the importance of Tregfci in understanding the molecular mechanism by which Tregs maintain the balance between systemic and local immune ecosystems. ETS1’s regulation of Tregfci transcriptomic and metabolic profiles were confirmed in human PBMCs treated with an ETS1 inhibitor and in lung tissues from miceETS1-cKO mice. Furthermore, Tregfci and ETS1 represent a distinct molecular signature of T cells and potential therapeutic targets for clinical intervention in lung cancer.